>Zolpimist is on the table having FDA approval. This has to be attractive to companies outside the US. (Suda does not have rights to the US >market)
I wouldnt rule out SUDA bringing in Amherst on a joint sale of worldwide rights, carving up the proceeds proportionately. This would be more attractive to global pharma, the whole being more than the sum of the parts. They kind of did something similar with London Pharma on Artimist in regards to broadening the rights from Africa to worldwide and adult, so there is precedent in this kind of deal. Obviously ECR and parent Valeant's current arrangement with Amherst may need consideration in this case.
- Forums
- ASX - By Stock
- ALA
- Bio-Europe Conference
Bio-Europe Conference, page-2
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ALA (ASX) to my watchlist
|
|||||
Last
15.0¢ |
Change
0.015(11.1%) |
Mkt cap ! $157.7M |
Open | High | Low | Value | Volume |
14.0¢ | 15.0¢ | 14.0¢ | $106.6K | 736.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 487932 | 14.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
14.5¢ | 50000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 487932 | 0.140 |
11 | 214680 | 0.135 |
9 | 427786 | 0.130 |
7 | 528775 | 0.125 |
10 | 526563 | 0.120 |
Price($) | Vol. | No. |
---|---|---|
0.145 | 50000 | 1 |
0.150 | 407532 | 7 |
0.155 | 387263 | 6 |
0.160 | 359150 | 9 |
0.165 | 230762 | 4 |
Last trade - 15.36pm 16/08/2024 (20 minute delay) ? |
Featured News
ALA (ASX) Chart |